Results 31 to 40 of about 447,577 (315)

Access to Diagnostics and Treatment for People With Metastatic EGFR-Positive NSCLC: Lessons From Project PRIORITY

open access: yesJTO Clinical and Research Reports
Introduction: The treatment landscape for people diagnosed with EGFR-mutated (EGFR-m) NSCLC has rapidly evolved, yet there remains limited self-reported information about the lived experience.
Jill Feldman, MA   +8 more
doaj   +1 more source

Expressions of TP53, PDGF and EGFR in Primary Astrocytomas and Their Correlation with Clinicopathological Features and Prognosis

open access: yesZhongliu Fangzhi Yanjiu, 2021
Objective To investigate the expression of TP53, PDGF and EGFR in primary astrocytomas, and analyze their correlation with clinicopathological features and prognosis.
SUN Xiaoling   +5 more
doaj   +1 more source

THE IMPORTANCE OF DETERMINING THE UROMODULIN SERUM CONCENTRATION IN DIABETES MELLITUS TYPE 2 PATIENTS

open access: yesSanamed, 2021
Introduction: In the kidney, cells in the thick ascending limb of the loop of the Henle synthesized uromodulin (UMOD). This study aims to present the evaluation of the uromodulin serum concentration in diabetes mellitus type 2 (T2DM) patients in the ...
Jordanova Elena   +4 more
doaj   +1 more source

EGFR-MET interaction is modulated by EGFR mutations.

open access: yes, 2017
(A) Western blot (WB) of total MET levels in H1975 derived cells. Tubulin levels are shown as loading control. Values beneath blots are relative levels of MET compared to the total levels in the H1975L858R/T790M cell line from 2 independent experiments +/
Elena Ortiz-Zapater (3708226)   +10 more
core   +1 more source

Transforming Growth Factor Alpha Stimulation of Mucosal Tissue Cultures from Head and Neck Squamous Cell Carcinoma Patients Increases Chemoresistance to Cisplatin [PDF]

open access: yes, 2010
The monoclonal epidermal growth factor receptor ( EGFR) antibody cetuximab (Erbitux(TM)) was recently approved by the European Medicines Agency for the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in combination ...
Baumeister, Philipp   +7 more
core   +1 more source

Antitumor Efficacy and Mechanisms of Lapatinib in Combination with Cisplatin on Esophageal Squamous Cancer Cells

open access: yesZhongliu Fangzhi Yanjiu, 2019
Objective To evaluate the antitumor efficacy of lapatinib in combination with cisplatin on esophageal squamous cell carcinoma (ESCC) and related mechanisms.
DOU Qiaohua   +4 more
doaj   +1 more source

Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway

open access: yes, 2009
This article has been made available through the Brunel Open Access Publishing Fund - Copyright @ 2009 Orton et al.BACKGROUND: The Epidermal Growth Factor Receptor (EGFR) activated Extracellular-signal Regulated Kinase (ERK) pathway is a critical cell ...
Gormand, A   +25 more
core   +2 more sources

Role of EGFR Juxtamembrane Domain in EGFR Activation [PDF]

open access: yesBiophysical Journal, 2011
The intracellular juxtamembrane domain of several receptor tyrosine kinases (RTKs) has been proposed to play an autoinhibitory role. The epidermal growth factor receptor (EGFR) has been widely used as a model in studies of the RTK activation mechanism.
He, Lijuan   +2 more
openaire   +1 more source

EGFR-Targeted Nanobody Functionalized Polymeric Micelles Loaded with mTHPC for Selective Photodynamic Therapy

open access: yes, 2020
meta-Tetra­(hydroxyphenyl)­chlorin (mTHPC) is one of the most potent second-generation photosensitizers, clinically used for photodynamic therapy (PDT) of head and neck squamous cell carcinomas.
Javier Sastre Toraño (1685377)   +19 more
core   +1 more source

Joint co-clustering: co-clustering of genomic and clinical bioimaging data [PDF]

open access: yes, 2007
For better understanding the genetic mechanisms underlying clinical observations, and better defining a group of potential candidates for protein-family-inhibiting therapy, it is interesting to determine the correlations between genomic, clinical data ...
Benini, L.   +19 more
core   +1 more source

Home - About - Disclaimer - Privacy